{
    "clinical_study": {
        "@rank": "26721", 
        "arm_group": [
            {
                "arm_group_label": "Rocuronium-placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.\nDuring surgical procedure, we will monitor train of four (TOF) using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will  measure time to take from TOF ratio 0.5 to 1.0"
            }, 
            {
                "arm_group_label": "Rocuronium-neostigmine 10 \u338d", 
                "arm_group_type": "Active Comparator", 
                "description": "At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.\nDuring surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 \u338d/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0."
            }, 
            {
                "arm_group_label": "Rocuronium-neostigmine 20 \u338d", 
                "arm_group_type": "Active Comparator", 
                "description": "At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.\nDuring surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 \u338d/kg will be injected. And we will  measure time to take from TOF ratio 0.5 to 1.0"
            }, 
            {
                "arm_group_label": "Rocuronium-neostigmine 40 \u338d", 
                "arm_group_type": "Active Comparator", 
                "description": "At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.\nDuring surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 \u338d/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
            }, 
            {
                "arm_group_label": "Cisatracurium-placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.\nDuring surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will  measure time to take from TOF ratio 0.5 to 1.0"
            }, 
            {
                "arm_group_label": "Cisatracurium-neostigmine 10 \u338d", 
                "arm_group_type": "Active Comparator", 
                "description": "At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.\nDuring surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 \u338d/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
            }, 
            {
                "arm_group_label": "Cisatracurium-neostigmine 20 \u338d", 
                "arm_group_type": "Active Comparator", 
                "description": "At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.\nDuring surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 \u338d/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
            }, 
            {
                "arm_group_label": "Cisatracurium-neostigmine 40 \u338d", 
                "arm_group_type": "Active Comparator", 
                "description": "At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.\nDuring surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 \u338d/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to find appropriate dose of neostigmine which is possible to reverse\n      rocuronium or cisatracurium till train of four (TOF) 0.9 within 10 minutes."
        }, 
        "brief_title": "Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Observation of Neuromuscular Block", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  American Society of Anesthesiologist Physical status classification 1 or 2 elective\n             surgery under general anesthesia\n\n        Exclusion Criteria:\n\n          -  BMI >25 or < 20 kg/m2\n\n          -  Patients taking intercurrent medication\n\n          -  Glutamic Oxalacetate Transaminase or Glutamic Pyruvate Transaminase > 40 IU/L, Cr >\n             1.4 mg/dl"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "69 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "112", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01885715", 
            "org_study_id": "B-1208/168-009", 
            "secondary_id": "Eunsu Choi"
        }, 
        "intervention": {
            "arm_group_label": [
                "Rocuronium-placebo", 
                "Rocuronium-neostigmine 10 \u338d", 
                "Rocuronium-neostigmine 20 \u338d", 
                "Rocuronium-neostigmine 40 \u338d", 
                "Cisatracurium-placebo", 
                "Cisatracurium-neostigmine 10 \u338d", 
                "Cisatracurium-neostigmine 20 \u338d", 
                "Cisatracurium-neostigmine 40 \u338d"
            ], 
            "description": "At induction, we will inject rocuronium 0.6 mg/kg for rocuronium arms and cisatracurium 0.15 mg/kg for cisatracurium arms.\nDuring surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected in placebo arms. And neostigmine 10, 20, or 40 \u338d/kg will injected in each arms.", 
            "intervention_name": "Injection of neostigmine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Neostigmine", 
                "Atracurium", 
                "Rocuronium", 
                "Cisatracurium"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 3, 2013", 
        "location": {
            "contact": {
                "last_name": "Eunsu Choi, professor", 
                "phone": "82-31-787-7499"
            }, 
            "facility": {
                "address": {
                    "city": "Seongnam-si", 
                    "country": "Korea, Republic of", 
                    "state": "Gyeonggi-do", 
                    "zip": "463-707"
                }, 
                "name": "Eunsu Choi"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "8", 
        "official_title": "Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium", 
        "overall_contact": {
            "email": "potterydoll@gmail.com", 
            "last_name": "Eunsu Choi, professor", 
            "phone": "82-31-787-7499"
        }, 
        "overall_official": {
            "affiliation": "Professor", 
            "last_name": "Ah Young Oh", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Korea: Food and Drug Administration", 
                "Korea: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary outcome of this study is how long it takes time to reverse from TOF ratio 0.5 to 1.0 after injection of different doses of neostigmine at the TOF 0.5", 
            "measure": "time to reverse from light muscle relaxation", 
            "safety_issue": "No", 
            "time_frame": "time from TOF 0.5 to TOF 1.0 after injection of different doses of neostigmine"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01885715"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Secondary outcome of this study is how long it takes time to reverse from TOF ratio 0.5 to 0.9 after injection of different doses of neostigmine at the TOF 0.5", 
            "measure": "time to reverse from TOF ratio 0.5 to 0.9", 
            "safety_issue": "No", 
            "time_frame": "time from TOF 0.5 to TOF 0.9 after injection of different doses of neostigmine"
        }, 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}